Page 2 - Zymeworks Inc News Today

Has released an update. Zymeworks Inc., a clinical-stage biotech firm, has announced their participation in the Bank of America Se...

VANCOUVER, British Columbia, April 30, 2024 -- Zymeworks Inc. , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the...

NEW YORK, April 28, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. . Such investors are advised to contact Danielle Peyton at...

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME). Such investors are advised

NEW YORK, April 20, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. . Such investors are advised to contact Danielle Peyton at...

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. ("Zymeworks" or the "Company") (NASDAQ: ZYME). Such investors...

NEW YORK, April 20, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980 The investigation concerns whether Zymeworks and certain of its officers and/or directors have engaged in securities […]

DekaBank Deutsche Girozentrale decreased its position in Zymeworks Inc. (NYSE:ZYME – Free Report) by 70.5% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 3,843 shares of the company’s stock after selling 9,191 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Zymeworks were worth $40,000 as […]

NEW YORK, April 12, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. . Such investors are advised to contact Danielle Peyton at...

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. ("Zymeworks" or the "Company") (NASDAQ: ZYME). Such investors...